Topics

Increased access could decrease unintended pregnancies and their associated costs

In November 2012, an emergent theme at the first National Sexual and Reproductive Health Conference, convened by the Public Health Association of Australia and Sexual Health and Family Planning Australia, was the need to increase access to and uptake of long-acting reversible contraception (LARC) methods, particularly by younger, highly fertile women. Compared with countries in northern Europe, Australia has a relatively high rate of unintended pregnancy and abortion (19.7 per 1000 women aged 15–44 years in Australia versus 17 per 1000 in northern Europe)1,2
yet a low uptake of the most effective methods of contraception — the LARC methods (used by 6.5% of women using contraception in Australia versus 14.8%
in northern Europe).3,4 These methods include:
3-monthly progestogen injections (depot medroxy-progesterone acetate); a progestogen-only (etonogestrel) subdermal implant with a duration of action of up to 3 years; and intrauterine contraceptive (IUC) methods — the hormonal levonorgestrel intrauterine system and copper intrauterine devices, which provide highly effective contraception for up to 5 and 10 years, respectively. Although data are lacking in Australia,
we can learn from the situation in the United States. Population surveys have found that half of unintended pregnancies in the US are attributable to failure of contraceptive methods that, to optimise success, require women to make a daily decision to use them.5 Interventions such as enhanced counselling and instituting immediate start of the contraceptive pill
have not consistently improved regularity of use and continuation rates or reduced the occurrence of unintended pregnancies. Adolescents and young women are especially vulnerable to unintended pregnancy, as they are highly fertile and may be less reliable in their contraceptive use.6

The full article is accessible to AMA members and paid subscribers. If you are an AMA member or have a subscription login to read more or purchase a subscription now.

All three authors work in the field of contraception. Kirsten Black is a consultant on an international advisory board for Bayer Healthcare and has been supported in this capacity to attend conferences as a presenting author; she has also received payment as a speaker. She is a registered trainer in implant insertion and removal for MSD. Deborah Bateson (formerly of Family Planning NSW) and Caroline Harvey have received individual support from Bayer Healthcare and MSD to attend national and international conferences. Family Planning NSW and Family Planning Queensland have been paid by MSD and Bayer Healthcare for the development of educational materials and teaching. Family Planning NSW is involved in clinical trials sponsored by pharmaceutical companies including Bayer Healthcare and MSD.

Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.